{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T07:13:54Z","timestamp":1772003634970,"version":"3.50.1"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T00:00:00Z","timestamp":1767916800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T00:00:00Z","timestamp":1767916800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Grunenthal GmbH, Germany"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dermatol Ther (Heidelb)"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1007\/s13555-025-01624-7","type":"journal-article","created":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T13:55:42Z","timestamp":1767966942000},"page":"1125-1145","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Progressive Improvements with Repeated High-Concentration Capsaicin Patch: Real-World Data from the Retrospective CASPAR German Pain e-Registry Study in Postherpetic Neuralgia"],"prefix":"10.1007","volume":"16","author":[{"given":"Sonja","family":"St\u00e4nder","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manuel P.","family":"Pereira","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6198-4806","authenticated-orcid":false,"given":"Mari\u00eblle","family":"Eerdekens","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lucia","family":"Garcia-Guerra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fabienne","family":"Percot","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Samuel","family":"Allen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rita","family":"Freitas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tamara","family":"Quandel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"\u00dcberall","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,1,9]]},"reference":[{"key":"1624_CR1","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofae211","volume":"11","author":"ZA Marcum","year":"2024","unstructured":"Marcum ZA, Jain P, Embry A, Arakaki B, Estevez I, Viscidi E. Incidence of herpes zoster and postherpetic neuralgia and herpes zoster vaccination uptake in a US administrative claims database. Open Forum Infect Dis. 2024;11:ofae211.","journal-title":"Open Forum Infect Dis"},{"key":"1624_CR2","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2014-004833","volume":"4","author":"K Kawai","year":"2014","unstructured":"Kawai K, Gebremeskel BG, Acosta CJ. Systematic review of incidence and complications of herpes zoster: towards a global perspective. BMJ Open. 2014;4:4833.","journal-title":"BMJ Open"},{"key":"1624_CR3","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1007\/s40121-024-00963-w","volume":"13","author":"A Marijam","year":"2024","unstructured":"Marijam A, Vroom N, Bhavsar A, Posiuniene I, Lecrenier N, Vroling H. Systematic literature review on the incidence of herpes zoster in populations at increased risk of disease in the EU\/EEA, Switzerland, and the UK. Infect Dis Ther. 2024;13:1083\u2013104.","journal-title":"Infect Dis Ther"},{"key":"1624_CR4","doi-asserted-by":"publisher","first-page":"1077","DOI":"10.1111\/bjd.19687","volume":"184","author":"HJ Forbes","year":"2021","unstructured":"Forbes HJ, Bhaskaran K, Grint D, et\u00a0al. Incidence of acute complications of herpes zoster among immunocompetent adults in England: a matched cohort study using routine health data. Br J Dermatol. 2021;184:1077.","journal-title":"Br J Dermatol"},{"key":"1624_CR5","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofw205","volume":"3","author":"F Marra","year":"2016","unstructured":"Marra F, Lo E, Kalashnikov V, Richardson K. Risk of herpes zoster in individuals on biologics, disease-modifying antirheumatic drugs, and\/or corticosteroids for autoimmune diseases: a systematic review and meta-analysis. Open Forum Infect Dis. 2016;3:ofw205.","journal-title":"Open Forum Infect Dis"},{"key":"1624_CR6","doi-asserted-by":"publisher","first-page":"e263","DOI":"10.1016\/S2666-7568(22)00039-3","volume":"3","author":"JF Mbinta","year":"2022","unstructured":"Mbinta JF, Simpson CR, Mbinta JF, et\u00a0al. Post-licensure zoster vaccine effectiveness against herpes zoster and postherpetic neuralgia in older adults: a systematic review and meta-analysis. Lancet Healthy Longev. 2022;3:e263\u201375.","journal-title":"Lancet Healthy Longev"},{"key":"1624_CR7","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1007\/s40266-012-0014-3","volume":"29","author":"S Nalamachu","year":"2012","unstructured":"Nalamachu S, Morley-Forster P. Diagnosing and managing postherpetic neuralgia. Drugs Aging. 2012;29:863\u20139.","journal-title":"Drugs Aging"},{"key":"1624_CR8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1741-7015-8-37","volume":"8","author":"RW Johnson","year":"2010","unstructured":"Johnson RW, Bouhassira D, Kassianos G, Lepl\u00e8ge A, Schmader KE, Weinke T. The impact of herpes zoster and post-herpetic neuralgia on quality-of-life. BMC Med. 2010;8:1\u201313.","journal-title":"BMC Med"},{"key":"1624_CR9","doi-asserted-by":"publisher","DOI":"10.1007\/s10389-011-0481-8","volume":"20","author":"K Lukas","year":"2011","unstructured":"Lukas K, Edte A, Bertrand I. The impact of herpes zoster and post-herpetic neuralgia on quality of life: patient-reported outcomes in six European countries. J Public Health. 2011;20:441.","journal-title":"J Public Health"},{"key":"1624_CR10","first-page":"409","volume-title":"European handbook of dermatological treatment","author":"PA Nair","year":"2023","unstructured":"Nair PA, Patel BC. Herpes zoster. In: Katsambas AD, Lotti TM, editors. European handbook of dermatological treatment. Cham, Switzerland: Springer; 2023. p. 409\u201316."},{"key":"1624_CR11","doi-asserted-by":"publisher","first-page":"1446","DOI":"10.1097\/j.pain.0000000000000935","volume":"158","author":"J Vollert","year":"2017","unstructured":"Vollert J, Maier C, Attal N, et\u00a0al. Stratifying patients with peripheral neuropathic pain based on sensory profiles: algorithm and sample size recommendations. Pain. 2017;158:1446\u201355.","journal-title":"Pain"},{"key":"1624_CR12","volume":"6","author":"JC Cappelleri","year":"2014","unstructured":"Cappelleri JC, Bienen EJ, Koduru V, Sadosky A. Measurement properties of painDETECT by average pain severity. Clinicoecon Outcomes Res. 2014;6:497.","journal-title":"Clinicoecon Outcomes Res"},{"key":"1624_CR13","doi-asserted-by":"publisher","first-page":"2177","DOI":"10.1111\/ene.15831","volume":"30","author":"A Truini","year":"2023","unstructured":"Truini A, Aleksovska K, Anderson CC, et\u00a0al. Joint European Academy of Neurology\u2013European Pain Federation\u2013Neuropathic Pain Special Interest Group of the International Association for the study of pain guidelines on neuropathic pain assessment. Eur J Neurol. 2023;30:2177\u201396.","journal-title":"Eur J Neurol"},{"key":"1624_CR14","doi-asserted-by":"publisher","first-page":"2271","DOI":"10.1056\/NEJMoa051016","volume":"352","author":"M Oxman","year":"2005","unstructured":"Oxman M, Levin M, Johnson G, et\u00a0al. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N Engl J Med. 2005;352:2271\u201384.","journal-title":"N Engl J Med"},{"key":"1624_CR15","doi-asserted-by":"publisher","DOI":"10.2196\/43893","volume":"9","author":"Q Wang","year":"2023","unstructured":"Wang Q, Yang L, Li L, Liu C, Jin H, Lin L. Willingness to vaccinate against herpes zoster and its associated factors across WHO regions: global systematic review and meta-analysis. JMIR Public Health Surveill. 2023;9:e43893.","journal-title":"JMIR Public Health Surveill"},{"issue":"Suppl 1","key":"1624_CR16","first-page":"S207","volume":"19","author":"M Gerald","year":"2013","unstructured":"Gerald M, Sacks M. Unmet need in the treatment of postherpetic neuralgia. Am J Manag Care. 2013;19(Suppl 1):S207\u201313.","journal-title":"Am J Manag Care"},{"key":"1624_CR17","first-page":"162","volume":"18","author":"D B\u0119ben","year":"2024","unstructured":"B\u0119ben D, Kowalewski J, Recka K, Micha\u0142ka D, Grzelak A, J\u0119drocha O, et\u00a0al. Post-herpetic neuralgia: currently available oral and topical medications in the management of pain\u2014A review. J Pre-Clin Clin Res. 2024;18:162\u20137.","journal-title":"J Pre-Clin Clin Res"},{"key":"1624_CR18","doi-asserted-by":"publisher","first-page":"447","DOI":"10.2147\/JMDH.S106340","volume":"9","author":"T Mallick-Searle","year":"2016","unstructured":"Mallick-Searle T, Snodgrass B, Brant JM. Postherpetic neuralgia: epidemiology, pathophysiology, and pain management pharmacology. J Multidiscip Healthc. 2016;9:447.","journal-title":"J Multidiscip Healthc"},{"key":"1624_CR19","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1016\/j.anclin.2019.04.007","volume":"37","author":"TM Andres","year":"2019","unstructured":"Andres TM, McGrane T, McEvoy MD, Allen BFS. Geriatric pharmacology: an update. Anesthesiol Clin. 2019;37:475\u201392.","journal-title":"Anesthesiol Clin"},{"key":"1624_CR20","unstructured":"European Medicines Agency. Qutenza 179 mg cutaneous patch. Summary of product characteristics; 2019. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/qutenza. Accessed 3 Jun 2025."},{"key":"1624_CR21","unstructured":"US Food and Drug Administration. QUTENZA\u00ae (capsaicin) topical system. US prescribing information; 2020. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2024\/022395s024lbl.pdf. Accessed 3 Jun 2025."},{"key":"1624_CR22","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1097\/j.pain.0000000000002735","volume":"164","author":"M Sendel","year":"2023","unstructured":"Sendel M, Dunst A, Forstenpointner J, H\u00fcllemann P, Baron R. Capsaicin treatment in neuropathic pain: axon reflex vasodilatation after 4 weeks correlates with pain reduction. Pain. 2023;164:534\u201342.","journal-title":"Pain"},{"key":"1624_CR23","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1097\/FTD.0b013e3181a8b200","volume":"31","author":"S Babbar","year":"2009","unstructured":"Babbar S, Marier JF, Mouksassi MS, et\u00a0al. Pharmacokinetic analysis of capsaicin after topical administration of a high-concentration capsaicin patch to patients with peripheral neuropathic pain. Ther Drug Monit. 2009;31:502\u201310.","journal-title":"Ther Drug Monit"},{"key":"1624_CR24","doi-asserted-by":"publisher","first-page":"668","DOI":"10.2340\/00015555-3188","volume":"99","author":"J Hidding","year":"2019","unstructured":"Hidding J, Agelopoulos K, Pereira MP, et\u00a0al. Sensory qualities point to different structural and functional skin patterns in chronic pruritus patients. A translational explorative study. Acta Derm Venereol. 2019;99:668\u201374.","journal-title":"Acta Derm Venereol"},{"key":"1624_CR25","doi-asserted-by":"publisher","DOI":"10.1136\/bmjdrc-2024-004864","volume":"13","author":"M \u00dcberall","year":"2025","unstructured":"\u00dcberall M, Quandel T, Engelen S, et\u00a0al. CASPAR: a retrospective cohort study of the high-concentration capsaicin topical system in patients with painful diabetic peripheral neuropathy of the feet. BMJ Open Diabetes Res Care. 2025;13:e004864.","journal-title":"BMJ Open Diabetes Res Care"},{"key":"1624_CR26","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.sjpain.2016.06.012","volume":"13","author":"GZ Heller","year":"2016","unstructured":"Heller GZ, Manuguerra M, Chow R. How to analyze the visual analogue scale: myths, truths and clinical relevance. Scand J Pain. 2016;13:67\u201375.","journal-title":"Scand J Pain"},{"key":"1624_CR27","unstructured":"National Committee for Quality Assurance. The Veterans RAND 12-Item Health Survey (VR-12). https:\/\/www.aaos.org\/globalassets\/quality-and-practice-resources\/patient-reported-outcome-measures\/quality-of-life\/veterans-rand-12-vr-12.pdf. Accessed 3 Jun 2025."},{"key":"1624_CR28","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/0304-3959(92)90154-4","volume":"50","author":"M Von Korff","year":"1992","unstructured":"Von Korff M, Ormel J, Keefe FJ, Dworkin SF. Grading the severity of chronic pain. Pain. 1992;50:133\u201349.","journal-title":"Pain"},{"key":"1624_CR29","unstructured":"Deutsche Gesellschaft f\u00fcr Schmerzmedizin e.V. (German Pain Society). iDocLive\u00ae Documentation Platform. https:\/\/www.dgschmerzmedizin.de\/. Accessed 3 Jun 2025."},{"key":"1624_CR30","doi-asserted-by":"publisher","unstructured":"Lovibond SH, Lovibond PF. Depression anxiety & stress scales; 1995. https:\/\/doi.org\/10.1037\/t01004-000","DOI":"10.1037\/t01004-000"},{"key":"1624_CR31","first-page":"55","volume":"18","author":"GE Gross","year":"2020","unstructured":"Gross GE, Eisert L, Doerr HW, et\u00a0al. S2k guidelines for the diagnosis and treatment of herpes zoster and postherpetic neuralgia. JDDG J Dtsch Dermatol Ges. 2020;18:55\u201378.","journal-title":"JDDG J Dtsch Dermatol Ges"},{"key":"1624_CR32","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.2147\/JPR.S435809","volume":"17","author":"G Pickering","year":"2024","unstructured":"Pickering G, Engelen S, Stupar M, Ganry H, Eerdekens M. Is the capsaicin 179 mg (8% w\/w) cutaneous patch an appropriate treatment option for older patients with peripheral neuropathic pain? J Pain Res. 2024;17:1327\u201344.","journal-title":"J Pain Res"},{"key":"1624_CR33","first-page":"1387","volume":"25","author":"J Gudin","year":"2019","unstructured":"Gudin J, Fudin J, Wang E, Haylon T, Patel K, Goss TF. Treatment patterns and medication use in patients with postherpetic neuralgia. J Manag Care Spec Pharm. 2019;25:1387\u201396.","journal-title":"J Manag Care Spec Pharm"},{"key":"1624_CR34","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2022.998904","volume":"13","author":"P Anand","year":"2022","unstructured":"Anand P, Privitera R, Donatien P, et\u00a0al. Reversing painful and non-painful diabetic neuropathy with the capsaicin 8% patch: clinical evidence for pain relief and restoration of function via nerve fiber regeneration. Front Neurol. 2022;13:998904.","journal-title":"Front Neurol"},{"key":"1624_CR35","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0150973","volume":"11","author":"C Mankowski","year":"2016","unstructured":"Mankowski C, Patel S, Trueman D, Bentley A, Poole C. Cost-effectiveness of capsaicin 8% patch compared with pregabalin for the treatment of patients with peripheral neuropathic pain in Scotland. PLoS ONE. 2016;11:e0150973.","journal-title":"PLoS ONE"},{"key":"1624_CR36","doi-asserted-by":"publisher","first-page":"A526","DOI":"10.1016\/j.jval.2014.08.1658","volume":"17","author":"J Darba","year":"2014","unstructured":"Darba J, Kaskens L, Villa G. Qutenza\u00ae estimated costs per patient in primary versus secondary care. A comparison between Qutenza\u00ae, pregabalin and lidocaine for the treatment of peripheral neuropathic pain. Value Health. 2014;17:A526.","journal-title":"Value Health"},{"key":"1624_CR37","doi-asserted-by":"publisher","first-page":"225","DOI":"10.35975\/apic.v23i2.1079","volume":"23","author":"MR Minhas","year":"2019","unstructured":"Minhas MR, Aboalkhair A, Alghamdi H. Post-herpetic neuralgia in elderly: can topical capsaicin 8% patch be considered as first-line therapy? Anaesth Pain Intens Care. 2019;23:225\u201330.","journal-title":"Anaesth Pain Intens Care"},{"key":"1624_CR38","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1016\/j.jpain.2005.01.359","volume":"6","author":"G Oster","year":"2005","unstructured":"Oster G, Harding G, Dukes E, Edelsberg J, Cleary PD. Pain, medication use, and health-related quality of life in older persons with postherpetic neuralgia: results from a population-based survey. J Pain. 2005;6:356\u201363.","journal-title":"J Pain"},{"key":"1624_CR39","doi-asserted-by":"publisher","DOI":"10.1111\/j.1742-1241.2009.02089.x","volume":"63","author":"RW Johnson","year":"2009","unstructured":"Johnson RW, McElhaney J. Postherpetic neuralgia in the elderly. Int J Clin Pract. 2009;63:1386.","journal-title":"Int J Clin Pract"}],"container-title":["Dermatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-025-01624-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13555-025-01624-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-025-01624-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T06:40:52Z","timestamp":1772001652000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13555-025-01624-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,9]]},"references-count":39,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["1624"],"URL":"https:\/\/doi.org\/10.1007\/s13555-025-01624-7","relation":{},"ISSN":["2193-8210","2190-9172"],"issn-type":[{"value":"2193-8210","type":"print"},{"value":"2190-9172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,9]]},"assertion":[{"value":"29 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Sonja St\u00e4nder has received grants or contracts from Almirall S.A., Beiersdorf A.G., Galderma S.A., Sanofi Genzyme Corporation, and Trevi Therapeutics Inc.; received consulting fees from AbbVie Deutschland GmbH & Co., Amgen Inc., Bellus Health Cough Inc., Bristol Myers Squibb Company, Clexio Biosciences Ltd., Galderma S.A., Klirna Biotech Inc., Omnicuris Healthcare Private Ltd., Pfizer Inc., P.G. Unna Academy, Sanofi-Aventis Deutschland GmbH, Sanofi-Aventis R&D, Sanofi Genzyme Corporation, and Vifor Pharma Deutschland GmbH; received payment or honoraria from lectures, presentations, speakers\u2019 bureau, and\/or manuscript writing or education writing from Beiersdorf A.G., CRM GmbH, FomF GmbH, Galderma Laboratorium GmbH, Galderma S.A., L\u2019Or\u00e9al, Novartis Pharma GmbH, Pfizer Pharma GmbH, P.G. Unna Akademie e.V., Sanofi-Aventis (Schweiz) A.G., Sanofi-Aventis Deutschland GmbH, Sanofi B.V., Sanofi Genzyme Europe B.V., Sanofi Genzyme Corporation, Sanofi Hong Kong Ltd., Sanofi OY, Streamed-Up! GmbH, TouchIME, UCB Pharma GmbH, Vifor Pharma Deutschland GmbH, and WebMD Global LLC; received support for attending meetings and\/or travel from AbbVie Deutschland GmbH & Co., Attovia Therapeutics Inc., Trevi Therapeutics Inc., Galderma Laboratorium GmbH, Sanofi-Aventis Deutschland GmbH, Lilly Deutschland GmbH, Pfizer Pharma GmbH, Sanofi Genzyme Corporation, and Vifor Pharma Deutschland GmbH; and participated on a data safety monitoring board or advisory board at Amgen Europe GmbH, Focus-Insight Healthtech Group Co. Ltd., Lilly Deutschland GmbH, Almirall Hermal GmbH, AbbVie Deutschland GmbH Co. KG, Almirall S.A., Celldex Therapeutics Inc., Galderma R&D, LLC., Galderma Laboratorium GmbH, Galderma S.A., Gr\u00fcnenthal GmbH, Lilly Deutschland GmbH, Regeneron Pharmaceuticals Inc., Sanofi Aventis Deutschland GmbH, Sanofi Genzyme Corporation, and Vifor Pharma Deutschland GmbH. Manuel P. Pereira has received research funding from Almirall, Clinuvel, and Pfizer; worked as a consultant for AbbVie, Galderma, Incyte, and Sanofi; was a speaker for AbbVie, Beiersdorf, Doctorflix, Eli Lilly, Falk Foundation, FomF GmbH, GA\n                      2\n                      LEN, Galderma, Novartis, P.G. Unna Academy, Sanofi, StreamedUP, TouchMDT, and Zai Lab; received travel fees from AbbVie, Celltrion, CSL Behring, GA\n                      2\n                      LEN, Galderma, Pfizer, and Sanofi; was an investigator for Allakos, Amgen, Celldex Therapeutics, Escient, Incyte, Mitsubishi, and Sanofi, and participated on a data safety monitoring board or advisory board at AbbVie, Galderma, and Sanofi. Mari\u00eblle Eerdekens, Lucia Garcia-Guerra, Fabienne Percot, Rita Freitas, and Tamara Quandel are employees of Gr\u00fcnenthal GmbH, Germany, or its affiliates. Samuel Allen is an employee of Averitas Pharma, USA. Michael \u00dcberall has received grants or contracts from Gr\u00fcnenthal GmbH, Strathmann, and Stada (all paid to institution); received consulting fees from Almirall, Gr\u00fcnenthal GmbH, Stada, and Dermapharm (all paid to institution); received payment or honoraria for lectures, presentations, speakers\u2019 bureaus, and manuscript writing or educational events from Averitas Pharma GRT Therapeutics, Gr\u00fcnenthal GmbH, GSK, Hexal, Johnson & Johnson, Mibe Pharmaceuticals, Nestl\u00e9, Neuraxpharm, Novartis, Strathmann, Teva, Tilray, Trommsdorff, and Viatris (all paid to institution); received payment for expert testimony from Averitas Pharma GRT Therapeutics (paid to institution); received support for attending meetings and\/or travel from Averitas Pharma GRT Therapeutics, Gr\u00fcnenthal GmbH, GSK, Teva, and Viatris (all paid to institution); participated on a data safety monitoring board or advisory board for Gr\u00fcnenthal GmbH and Viatris (all paid to institution); and had a leadership or fiduciary role on another board for the German Pain Association and German Pain League (all personal).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This noninterventional cohort study was conducted in accordance with the Declaration of Helsinki and relevant national and regulatory requirements. All participants (physicians and patients) provided their written informed consent prior to participation in the GPeR, authorizing the use of their anonymized data for healthcare research purposes.\u00a0The study concept and evaluation of anonymized data from the GPeR were reviewed and approved by the steering committees of the German Pain Association and the German Pain League, with the latter paying particular attention to ensuring that patients\u2019 rights are upheld within the framework of this study. Since this retrospective study only refers to depersonalized data (i.e., of patients, physicians, and treatment facilities) from routine care, no approval from an ethics committee was required. The study concept has been registered in the European Medicines Agency registry for noninterventional\/epidemiological studies (European post\u2010authorization study [EU PAS] identifier: 1000000106) to make this evaluation public. CASPAR is registered with the European Network of Centers for Pharmacoepidemiology and Pharmacovigilance in the European Union Electronic Registry of Post-Authorization Studies. All analyses were performed using only anonymized data to comply with German guidelines on protection of data privacy and with the European Union General Data Protection Regulation.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}